Sun Pharma to Acquire Organon in All-Cash Deal to Resolve Debt Burden

Organon (NYSE: OGN) shares surged nearly 17% on Monday following the announcement that Sun Pharmaceutical Industries will acquire the company in an all-cash deal. The stock closed at $13.16, with trading volume exploding to 133.6 million shares, representing a massive spike of approximately 1,618% over its three-month average. The acquisition is expected to be priced at $14 per share. This follows a period of intense speculation, as the company had already seen a 30% jump the previous Friday amid reports that Sun Pharma, German pharma Grünenthal, and Swedish private equity firm EQT were each considering bids. The deal comes as a lifeline for Organon, which has seen its share price drop 60% since its 2021 spin-off from Merck. The company is currently burdened by $8 billion in long-term debt, which has resulted in annual interest payments of approximately $500 million—a significant drain on profitability as margins waned. While the broader indices remained relatively flat, with the S&P 500 and Nasdaq posting marginal gains, Organon significantly outperformed its pharmaceutical peers. Pfizer and Bristol Myers Squibb both closed lower on Monday, highlighting that Organon's gains were driven specifically by the buyout news rather than a sector-wide rally. The transaction is slated to close in early 2027, pending customary shareholder approvals.